Actelion and Johnson & Johnson submit potential deal to Swiss authorities

Swiss biotech Actelion and Johnson & Johnson have submitted to the Switzerland’s takeover board the $28bn deal the two groups have reached after resuming talks after Christmas. Actelion, founded in 1997 by Jean-Paul Clozel, former Roche’s executive, has a workforce of over 2,500 employees and generated more than CHF2bn in sales in 2016. The company focuses on the control of intrapulmonary pressure, with Tracleer, Opsumit and Uptravi. Under the terms of the deal on which the two parties are working, a new company including Actelion’s research activities will be reportedly created, will be listed and will become independent from the same Actelion. Research, with over 800 employees, is the real driver of development for Actelion and requires a minimum of $2bn to continue operating and ensure the pipeline development. (Source Tages Anzeiger)